-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The impact of body mass index (BMI) on clinical outcomes in patients with atrial fibrillation remains controversial, especially in Asian populations.
, researchers aimed at assessing the correlation between BMI and clinical outcomes in Asian atrial fibrillation patients treated with oral anticoagulants, according to a recent study published in the authoritative journal Stroke on Cardiovascular Disease.
researchers used the Korean National Health Insurance Database from January 2015 to December 2017 to identify new users of oral anticoagulants in patients with non-valve atrial fibrillation with BMI information available.
researchers analyzed ischemic stroke, intracranial bleeding, hospitalization of gastrointestinal bleeding, haemorrhage, all-cause death, and comprehensive clinical outcomes based on the BMI category.
43,173 patients were included in different BMI (kg/m2) groups: 3% underweight (-lt;18.5), 28% normal (18.5-23), 24% overweight (23-25), 39% obese I (25-30), and 6% obese grade II (≥30).
higher BMI (5 kg/m2 per increase) and ischemic stroke (risk ratio of 0.891 (95% CI 0.801-0.992)), gastrointestinal bleeding Hospitalization (HR is 0.785 (95% CI is 0.658-0.937) and haemorrhage (HR is 0.794 (95% CI is 0.686-95% CI) 0.919), all-cause death (HR is 0.658 (95% CI is 0.605-0.716) and comprehensive clinical outcome (HR is 0.751 %CI is 0.706-0.799) with a lower risk correlation, with the exception of intracranial bleeding (HR is 0.815 (95% CI is 0.627-1.061).
underweight was associated with an increased risk of integrated clinical outcomes (HR of 1.398 (95% CI of 1.170-1.671)), the main reason was an increased risk of all-cause death.
in different BMI groups, non-vitamin K antagonists had similar effects on clinical outcomes in patients with oral anticoagulants and huafalin.
, it can be seen that elevated BMI is associated with a lower risk of ischemic stroke and haemorrhage.
underweight patients were at higher risk of death and integrated clinical outcomes.
BMI for patients with atrial fibrillation should be determined based on a combination of treatments.
